Status:
COMPLETED
Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 Diabetes
Lead Sponsor:
LifeScan
Collaborating Sponsors:
Synexus(UK)
CPS(UK)
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Clinical benefits of the OneTouch® Ultra®2 BGMS versus standard BGMS during 52 weeks of use.
Eligibility Criteria
Inclusion
- ·
- Current diagnosis of type 2 diabetes
- Diagnosed at least 3 months prior to the start of the study but not more than 15 years from the start of the study
- Stable regimen (i.e., no changes in therapeutic regimen) for the past three months
- Baseline HbA1c of 7.0 to 8.9%, inclusive
Exclusion
- Using insulin
- Using oral agents that target post-prandial hyperglycemia (Note: These medications may be added during the study)
- Known history of anemia or disorders associated with anemia
- Has previously used the devices being tested in the study
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT00401622
Start Date
October 1 2006
End Date
January 1 2009
Last Update
May 15 2019
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85018
2
San Diego, California, United States, 92161
3
Wilmington, Delaware, United States, 19805
4
Hollywood, Florida, United States, 33023